Latest / Stock Movers / CVC Drops, Mankind Rises, Revolution Medicines Drops on Merck News
Transcript
- 0:02Speaker 1: Bloomberg Audio Studios, podcasts, radio news.
- 0:08Speaker 2: The Stock Movers Report, your roundup of companies making moves
- 0:12Speaker 2: in the stock market, harnessing the power of Bloomberg data.
- 0:16Speaker 1: Let's take a look at some stocks that are on
- 0:18Speaker 1: the move today.
- 0:18Speaker 2: We can do that.
- 0:19Speaker 1: We're joined by bloombergs Isabel Lee Isbell. What are you
- 0:21Speaker 1: looking at today? Let's start with CVC Capital Partners. It's
- 0:24Speaker 1: an Amsterdam listed firm and they agreed to buy Marathon
- 0:27Speaker 1: Asset Management. So this is a part of their efforts
- 0:29Speaker 1: to widen their footprint in US credit markets. See A
- 0:32Speaker 1: group in a note said that the Marathon deal allows
- 0:35Speaker 1: CVC to fill the white space that is in the
- 0:37Speaker 1: US credit market and should allow them to really just grow,
- 0:40Speaker 1: and especially in two areas, which is private wealth and insurance.
- 0:44Speaker 1: So CBC's a Amsterdam based firm. Ticker CVC it stands
- 0:47Speaker 1: lightly by one percent, but still it's good news for
- 0:51Speaker 1: the company. The deal includes earn up consideration linked to
- 0:54Speaker 1: Marathon's future financial performance over twenty twenty seven to twenty
- 0:57Speaker 1: twenty nine. I mean most deals have that.
- 0:59Speaker 2: All right stuff?
- 1:00Speaker 1: What's next on your list as well? Mankind tickeris MNKD.
- 1:04Speaker 1: The stock is barely hanging in there, up by four
- 1:07Speaker 1: tens of one percent. We have the FDA approving and
- 1:10Speaker 1: updated the company's inhaled insulin, So this was the first
- 1:14Speaker 1: time I heard that there's such a thing, and it's
- 1:15Speaker 1: revising recommendations for the starting meal time dosage. The revised
- 1:19Speaker 1: recommendation are for a FRESA that's the inhaled insulin that
- 1:22Speaker 1: approved to improve glycemic control and adult patients with diabetes melodists.
- 1:27Speaker 1: So revisions include recommended those conversions from injected meal time
- 1:31Speaker 1: insulin or insulin pumps. So that's good news for the stock.
- 1:35Speaker 1: I feel like with these companies it's always whenever there's
- 1:37Speaker 1: an FDA approval or any regulatory news, the stock religious spikes.
- 1:41Speaker 2: Hire would they move they can move.
- 1:42Speaker 1: Down to yes, I meant remove lawer, Yeah, I mean.
- 1:45Speaker 2: You've got to be on your toes with those kinds
- 1:47Speaker 2: of name.
- 1:47Speaker 1: How about Revolution Medicines, This one is really moving a
- 1:51Speaker 1: lot lower, down by twenty percent. Tickeris are vmds, So
- 1:54Speaker 1: they slid after Wall Street Journal reported that Merk and
- 1:57Speaker 1: the talks to acquire a biotech firm, citing people familar
- 2:00Speaker 1: with the matter, and this came after the two companies
- 2:03Speaker 1: couldn't agree on a price, so the deal, if it happened,
- 2:07Speaker 1: could have valued Revolution Medicines at around thirty billion dollars,
- 2:10Speaker 1: the report said, adding that talks could restart or maybe
- 2:13Speaker 1: another suitor could emerge. So mark Is really has been
- 2:16Speaker 1: looking for deals that will strengthen its treatments to counter
- 2:19Speaker 1: pit patent losses that erode tales around eighteen billion dollars
- 2:23Speaker 1: in the next years.
- 2:25Speaker 2: The Stock Mover's report from Bloomberg Radio. Check back with
- 2:29Speaker 2: us throughout the day for the latest roundup of companies
- 2:32Speaker 2: making news on Wall Street and for the latest market
- 2:35Speaker 2: moving headlines. Listen to Bloomberg Radio Live, catch us on YouTube,
- 2:40Speaker 2: Bloomberg dot com, and on Applecarplay and Android Auto with
- 2:43Speaker 2: the Bloomberg Business app.